Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure
| العنوان: | Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure |
|---|---|
| المؤلفون: | Krul, Inge M, Opstal-van Winden, Annemieke W J, Aleman, Berthe M P, Janus, Cécile P M, van Eggermond, Anna M, De Bruin, Marie L, Hauptmann, Michael, Krol, Augustinus D G, Schaapveld, Michael, Broeks, Annegien, Kooijman, Karen R, Fase, Sandra, Lybeert, Marnix L, Zijlstra, Josée M, van der Maazen, Richard W M, Kesminiene, Ausrele, Diallo, Ibrahima, de Vathaire, Florent, Russell, Nicola S, van Leeuwen, Flora E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
| المساهمون: | Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Radiotherapy, CCA - Cancer Treatment and quality of life, Hematology, APH - Quality of Care, Epidemiology and Data Science |
| المصدر: | International Journal of Radiation Oncology-Biology-Physics, 99(4), 843-853 International Journal of Radiation Oncology, Biology, Physics, 99, 4, pp. 843-853 International Journal of Radiation Oncology, Biology, Physics, 99, 843-853 Krul, I M, Opstal-van Winden, A W J, Aleman, B M P, Janus, C P M, van Eggermond, A M, De Bruin, M L, Hauptmann, M, Krol, A D G, Schaapveld, M, Broeks, A, Kooijman, K R, Fase, S, Lybeert, M L, Zijlstra, J M, van der Maazen, R W M, Kesminiene, A, Diallo, I, de Vathaire, F, Russell, N S & van Leeuwen, F E 2017, ' Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma : Influence of Gonadal Hormone Exposure ', International Journal of Radiation Oncology Biology Physics, vol. 99, no. 4, pp. 843-853 . https://doi.org/10.1016/j.ijrobp.2017.07.016 International Journal of Radiation Oncology Biology Physics, 99(4), 843-853. Elsevier Inc. International journal of radiation oncology, biology, physics, 99(4), 843. Elsevier |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Neoplasms, Radiation-Induced, Time Factors, medicine.medical_treatment, Menopause, Premature, Procarbazine, Noninfiltrating, 0302 clinical medicine, Risk Factors, Neoplasms, Taverne, 030212 general & internal medicine, Breast, Survivors, Young adult, Gonadal Steroid Hormones, Netherlands, Radiation, Radiotherapy Dosage, Middle Aged, Alkylating, Hodgkin Disease, Menopause, 030220 oncology & carcinogenesis, Female, medicine.drug, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, medicine.medical_specialty, Hormone Replacement Therapy, Intraductal, Antineoplastic Agents, Breast Neoplasms, Dose-Response Relationship, 03 medical and health sciences, Young Adult, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, Journal Article, medicine, Confidence Intervals, Humans, Radiology, Nuclear Medicine and imaging, Premature, Antineoplastic Agents, Alkylating, Gynecology, business.industry, Carcinoma, Ovary, Case-control study, Dose-Response Relationship, Radiation, Odds ratio, medicine.disease, Radiation therapy, Carcinoma, Intraductal, Noninfiltrating, Radiation-Induced, Case-Control Studies, business, Hormone |
| الوصف: | Item does not contain fulltext BACKGROUND: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk. METHODS: We conducted a nested case-control study among female 5-year HL survivors treated before age 41. Hormone exposure and HL treatment data were collected through medical records and questionnaires for 174 BC case patients and 466 control patients. Radiation dose to breast tumor location was estimated based on RT charts, simulation films, and mammography reports. RESULTS: We observed a linear radiation dose-response curve with an adjusted excess odds ratio (EOR) of 6.1%/Gy (95% confidence interval [CI]: 2.1%-15.4%). Women with menopause /=50 years. BC risk increased by 6.4% per additional year of post-RT intact ovarian function (P/=2 years did not increase BC risk (OR, 0.86; 95% CI, 0.32-2.32), whereas this risk was nonsignificantly increased among women without early menopause (OR, 3.69; 95% CI, 0.97-14.0; P for interaction: .06). Stratification by duration of post-RT intact ovarian function or HRT use did not statistically significantly modify the radiation dose-response curve. CONCLUSIONS: BC risk in female HL survivors increases linearly with radiation dose. HRT does not appear to increase BC risk for HL survivors with therapy-induced early menopause. There are no indications that endogenous and exogenous gonadal hormones affect the radiation dose-response relationship. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2017.07.016 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e41e90cad74c87cd8212f407613cf9 http://hdl.handle.net/1887/115416 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e5e41e90cad74c87cd8212f407613cf9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 03603016 |
|---|---|
| DOI: | 10.1016/j.ijrobp.2017.07.016 |